All In Biotech

Drug Trial Radar · NCT02512510

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 611 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

611

Actual

Start

Sep 2015

Primary completion

Aug 2016

Study completion Sep 2016

Sponsor

Lead sponsor
Mylan Inc.Industry
Sponsor type
Industry
Collaborators
Theravance Biopharma
First posted
Jul 31, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • TD-4208Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Trough FEV1 on Day 85Time frame: Baseline and Day 85

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Palmetto Medical Research Associates L.L.C.

    Easley, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.